Analysts expect Y-mAbs Therapeutics to report an earnings per share (EPS) of $-0.15.
Investors in Y-mAbs Therapeutics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Overview of Past Earnings
The company's EPS missed by $0.08 in the last quarter, leading to a 8.74% increase in the share price on the following day.
Here's a look at Y-mAbs Therapeutics's past performance and the resulting price change:
Quarter
Q2 2024
Q1 2024
Q4 2023
Q3 2023
EPS Estimate
-0.13
-0.14
-0.20
-0.19
EPS Actual
-0.21
-0.15
-0.02
-0.18
Price Change %
9.0%
-21.0%
12.0%
10.0%
Performance of Y-mAbs Therapeutics Shares
Shares of Y-mAbs Therapeutics were trading at $15.69 as of November 06. Over the last 52-week period, shares are up 215.45%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
Analyst Insights on Y-mAbs Therapeutics
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Y-mAbs Therapeutics.
The consensus ...